NCT05367440 - Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer | Biotech Hunter

Enrollment

175

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

April 17, 2031

Study Completion Date

April 17, 2031

Conditions

Metastatic Prostate Cancer

Interventions

DRUG

AZD5305

Patients will receive an oral dose of AZD5305 once daily

DRUG

Enzalutamide

Patients will receive an oral dose of Enzalutamide once daily

DRUG

Abiraterone Acetate

Patients will receive an oral dose of Abiraterone Acetate once daily

DRUG

Darolutamide

Patients will receive an oral dose of Darolutamide twice daily

DRUG

Apalutamide

Patients will receive an oral dose of Apalutamide once daily

Trial Locations (27)

2010

RECRUITING

Research Site, Darlinghurst

2050

RECRUITING

Research Site, Camperdown

2065

RECRUITING

Research Site, St Leonards

3002

RECRUITING

Research Site, East Melbourne

3004

RECRUITING

Research Site, Melbourne

3084

RECRUITING

Research Site, Heidelberg

10043

RECRUITING

Research Site, Orbassano

10060

RECRUITING

Research Site, Candiolo

13210

RECRUITING

Research Site, Syracuse

19111

WITHDRAWN

Research Site, Philadelphia

20133

RECRUITING

Research Site, Milan

20141

RECRUITING

Research Site, Milan

27100

RECRUITING

Research Site, Pavia

29572

RECRUITING

Research Site, Myrtle Beach

35128

RECRUITING

Research Site, Padua

46202

WITHDRAWN

Research Site, Indianapolis

48201

RECRUITING

Research Site, Detroit

48202

RECRUITING

Research Site, Detroit

77030

RECRUITING

Research Site, Houston

77094

RECRUITING

Research Site, Houston

92123

WITHDRAWN

Research Site, San Diego

CB2 0QQ

RECRUITING

Research Site, Cambridge

G12 0YN

RECRUITING

Research Site, Glasgow

SO16 6YD

WITHDRAWN

Research Site, Hampshire

M20 4BX

RECRUITING

Research Site, Manchester

NE7 7JA

WITHDRAWN

Research Site, Newcastle upon Tyne

PL6 8DH

RECRUITING

Research Site, Plymouth